Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

We are looking forward ... to our fiscal year end of June 30, 2016 and we hope to announce/have announced:

Start of Kevetrin advanced study in ovarian cancer.
Start of Brilacidin ABSSSI Phase 3
Start of Brilacidin for Ulcerative Proctitis proof of concept trial (phase 2)
Top line data on Kevetrin Phase 1 trial for advanced solid tumors
Top line data on Prurisol Phase 2 trial for chronic plaque psoriasis
Interim analysis for Brilacidin Phase 2 trial for Oral Mucositis
Start of Retinoblastoma program, formulation and toxicity studies
Additional ototoxicity studies with Brilacidin in different concentrations
Gram- negative and anti-fungal progress
Submission of grant application for study of Kevetrin in Pancreatic cancer with renowned hospital.

Let's take this as a "promissory note". If it all happens, we will be on the NASDAQ with $$$$. If little of it happens, well, then we will just have to re-evaluate things.